Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status

Frontiers in Immunology

Eriko Fukuda¹  Kazuki M. Matsuda²  Satoshi Ebata²  Ayumi Yoshizaki²  Takuya Miyagawa²  Ruriko Kawanabe²  Ai Kuzumi²  Teruyoshi Hisamoto²  Asako Yoshizaki-Ogawa²  Shinichi Sato²  Takemichi Fukasawa²  Yuta Norimatsu²  Hirohito Kotani²  Naoki Goshima⁴  Kei Yamaguchi⁴  Koji Ogawa⁴  Chihiro Ono⁴  Taishi Okumura⁴ 

[1] Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan;Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan;Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan;ProteoBridge Corporation, Tokyo, Japan;

关键词: autoantibody;    protein array;    autoimmunity;    inflammatory disease;    malignancy;   

DOI  :  10.3389/fimmu.2022.893086

来源: DOAJ

【 摘 要 】

Autoantibodies are found in various pathological conditions such as autoimmune diseases, infectious diseases, and malignant tumors. However their clinical implications have not yet been fully elucidated. Herein, we conducted proteome-wide autoantibody screening and quantification with wet protein arrays consisting of proteins synthesized from proteome-wide human cDNA library (HuPEX) maintaining their three-dimensional structure. A total of 565 autoantibodies were identified from the sera of three representative inflammatory disorders (systemic sclerosis, psoriasis, and cutaneous arteritis). Each autoantibody level either positively or negatively correlated with serum levels of C-reactive protein, the best-recognized indicator of inflammation. In particular, we discovered total levels of a subset of autoantibodies correlates with the severity of clinical symptoms. From the sera of malignant melanoma, 488 autoantibodies were detected. Notably, patients with metastases had increased overall autoantibody production compared to those with tumors limiting to the primary site. Collectively, proteome-wide screening of autoantibodies using the in vitro proteome can reveal the “autoantibody landscape” of human subjects and may provide novel clinical biomarkers.

【 授权许可】

Unknown